As we learn more about the etiology and cancer risks associated with Lynch syndrome (LS), the phenotypic spectrum of this condition and its genotype-phenotype correlations are being elucidated. We report a patient with past history of multiple cancers including colon and kidney cancer, and recently diagnosed with jejunal adenocarcinoma. The patient had microsatellite instability and immunohistochemistry (MSI/IHC) testing performed on his small bowel cancer in order to evaluate his risk for LS. The MSI/IHC results on his tumor tissue were reported as abnormal and subsequent blood draw revealed the presence of a germline MSH6 mismatch repair gene mutation. This case highlights the phenotypic variability of LS and complications it may present in evaluation for diagnosis and appropriate surveillance and management recommendations. To our knowledge, this is the first report of MSI/IHC being done on small bowel cancer to evaluate for this condition and subsequently confirmed via molecular analysis.
Introduction
Lynch syndrome (LS), otherwise known as hereditary nonpolyposis colorectal cancer (HNPCC), is an autosomal dominant hereditary cancer condition associated with germline mutations in the mismatch repair genes MLH1, MSH2, MSH6 and PMS2. Although variable, the lifetime risk of developing colorectal cancer with LS is approximately 80%, with male carriers having a somewhat higher cumulative risk as compared to females [1] [2] [3] . Female carriers additionally have an increased risk to develop endometrial cancer, with a cumulative lifetime risk of 27-71% [2, 4, 5] . Individuals with LS additionally have an increased lifetime risk to develop extra-colonic cancers, albeit to a somewhat lesser degree. These include ovarian, gastric, urinary tract, biliary tract and pancreas, small bowel, brain and skin cancers. More recent studies on Lynch syndrome have emphasized the phenotypic variability of this condition, as well as uncovering differences in cancer risk and age of onset with respect to the particular mismatch repair gene involved.
The preferred method of genetic testing for LS is to initially perform microsatellite instability (MSI) analysis and/or immunohistochemistry (IHC) staining as a test on the tumor tissue of an affected individual. If abnormal, this testing would indicate that a germline mismatch repair gene mutation is more likely to explain the cancer and, if IHC is performed, may also indicate which gene to test first via molecular analysis on a blood sample. It should be noted that although MSI is characteristic of LS-associated tumors, it may also be found in about 15% of unselected groups of colorectal cancer, and of this subset the majority (75-80%) are sporadic MSI due hypermethylation of the MLH1 promotor [6] . In addition, IHC may be difficult to interpret in some circumstances and its accuracy often relies on expertise of the pathologist [7] .
Although MSI/IHC in some cases may demonstrate false positive and false negative results, it is overall a more streamlined and cost-effective approach in the identification of LS. Hampel et al. [8] recently published results from a prospective study of LS in 500 newly diagnosed colon cancer patients irrespective of age, and the found the sensitivity of IHC in this population to be 94%. Studies performed on endometrial tumor tissue have revealed similar findings; Modica et al. [9] demonstrated 91% sensitivity and 83% specificity in predicting MSI-high cancers when all four proteins were examined, and Cohn et al. [10] found that IHC was able to predict a MLH1 or MSH2 mutation in 95% of cases. MSI/IHC testing has been more widely validated for colon and endometrial cancers as opposed to other cancers associated with this condition. There have been a number of reports on using this screening with ovarian cancers, sebaceous adenomas, and a few other extra-colonic Lynch-associated cancers, albeit to a much lesser degree [11] [12] [13] [14] [15] [16] [17] . Clarifying the efficacy of MSI/IHC in these other extra-colonic cancers is important, as the phenotypic variability and atypical presentation with Lynch syndrome continues to be revealed.
We present here a case of LS with an atypical presentation, identified via MSI/IHC performed on small bowel adenocarcinoma tissue and confirmed with MSH6 molecular genetic analysis on blood sample. This case illustrates not only the phenotypic variability of this condition, but also suggests that testing by MSI/IHC may be very feasible as a first step in LS identification using tumor tissue beyond what has been traditionally reported in the literature.
Case report
Genetics was consulted on a 66-year-old Northern European male who was admitted to the hospital for a partial small-bowel resection due to a recently-identified jejunal adenocarcinoma. This tumor was a moderately-differentiated adenocarcinoma arising in a polypoid, sessile villous adenoma. Several foci of submucosal extension were present with extension into the muscularis propria and, in one area, associated with a mucinous component. The patient had an extensive history of cancer, including an ascending colon cancer and renal cell carcinoma that were diagnosed synchronously at age 64. At that time, he underwent a partial right colectomy and a nephrectomy. He had a colonoscopy shortly before his surgery which revealed the presence of two tubular adenomas that were negative for high-grade dysplasia; one located in the ascending colon and the other in the rectum. The patient additionally had an oral tumor removed several years prior, around age 59, for which records were not available. He is noted to have an extensive past history of smoking.
Family history was significant for multiple cancers (Fig. 1 ). This included a sister with glioblastoma multiforme at age 63, a niece with gastric cancer at age 47, another niece with bilateral breast cancer at age 51, a nephew who had a cancerous tumor removed from his neck around age 50, and another niece who had breast cancer at age 33. The latter niece was noted to have a maternal family history of breast cancer through the patient's sisterin-law, who would be unrelated by blood. In addition, the patient's mother was noted to have breast cancer at age 80 followed by what was thought to be cervical cancer at age 85, although this was later confirmed as being endometrial cancer once records were obtained. There is one maternal aunt with breast cancer around age 50.
Although it was not a classic family history presentation of LS and with mostly later ages of cancer diagnosis, because the patient had multiple Lynch-associated cancers MSI/IHC was pursued on the available small bowel tumor tissue following genetics consultation. The IHC staining revealed absent MSH6 expression, while other markers (MLH1, MSH2 and PMS2) had normal expression ( Fig. 2 ). In addition, MSI was reported as being MSI-H in 5/5 markers. After he was released from the hospital, the patient returned to the genetics clinic for a follow-up consultation regarding his test results, and he opted to pursue molecular genetic testing with MSH6 gene analysis via blood draw. This test revealed the presence of a heterozygous MSH6 gene sequence variation, reported as 3202C [ T (R1068X), which is predicted to result in premature truncation of the MSH6 protein at amino acid position 1,068 and therefore representative of a pathogenic mutation.
Discussion
This case highlights some of the current challenges in the identification and management of individuals and families with LS. The patient and his family did not have a ''classical'' presentation of Lynch syndrome (LS), with ages of diagnosis being a later age of onset and, at the time of consultation, no known family history of colorectal or endometrial cancer. However, the patient's family does meet the revised Amsterdam criteria which would suggest this diagnosis. In the past there have been a few reports on the efficacy of performing MSI and IHC on extra-colonic, extra-endometrial tumor tissue to evaluate for LS. To our knowledge, this is the first report in the literature where both IHC and MSI have been performed on jejunal adenocarcinoma with informative results that were subsequently confirmed by molecular analysis on blood sample.
Recent studies on LS have highlighted the phenotypic variability of this condition, as well as elucidating some general genotype-phenotype correlations. The average age of diagnosis of these cancers has historically and consistently been reported as younger than that of the general population. However, more recent study using widespread evaluation for LS have found that the average of onset may be later than traditionally recognized with respect to colorectal cancer [18] . It has also been discovered that phenotypic presentation of Lynch syndrome is more likely to be atypical depending on the gene involved. For example, MSH6 germline mutations have been associated with a higher cumulative risk of endometrial cancer with a later age of onset as compared to other mismatch repair gene mutations [5, [19] [20] [21] [22] , and PMS2 mutations may also confer a higher risk for later-onset LS-associated cancers with a lower penetrance [23] . In addition, cancers other than those of the colon and endometrium account for about 30% of cancers in MLH1 and MSH2 carriers, but may account for as much as 50% in carriers of MSH6 gene mutations [24] . Consistent with previous reports on individuals with MSH6 germline mutations, the age of onset of cancers both for the patient and within his family are at a later age. The patient's mother is the only known case of endometrial cancer in the family and was diagnosed at age 85.
The patient in this case was recognized for genetics consultation once diagnosed with small bowel cancer, although he had been diagnosed with both colon and kidney cancer a few years prior. Small bowel cancer has been reported in association with Lynch syndrome at a lifetime risk of 4% [25] . Tumors are more likely to be located in the duodenum or the jejunum (such as with our patient), with a smaller proportion in the ileum. It is reported to be less common in association with MSH6 and PMS2 mutations as compared to MLH1 and MSH2, and has been reported to demonstrate MSI in most cases [26] .
The glioblastoma multiforme (GBM) in the patient's sister is a recognized, although rare, manifestation with LS and is often referred to as the Turcot variant of this condition. Brain cancer (most commonly GBM or astrocytoma) has been reported with LS at an estimated lifetime risk of 2% for MLH1 and MSH2 mutation carriers [27] , although the risk has not been well clarified for MSH6 mutations. It is interesting to note the high incidence of breast cancer in this patient's family, including early-onset and bilateral breast cancer. Breast cancer is not widely recognized as a cancer associated with LS, although more recent data have suggested a possible moderate increased risk within these families [28] .
Genetic testing to confirm a mutation for a hereditary cancer condition such as LS allows for knowledge of risk to develop specific cancers, in order to guide medical management decisions such as increased/enhanced surveillance for early detection, chemoprevention, and preventative surgical options. Surveillance recommendations for LS include semi-annual to annual colonoscopy starting at age 20-25 years or 10 years prior to the youngest age of diagnosis in the family. Females with Lynch syndrome are encouraged to consider surveillance versus preventative options with regard to their risk for developing gynecologic cancer. It has been suggested that in families with MSH6 mutations, the age of onset of surveillance for colonoscopy be initiated by age 30-35 as opposed to 20-25 years, and this recommendation has been adopted by the NCCN.
The efficacy of surveillance for other extra-colonic cancers in LS is widely debated and largely based on family history of these cancers. Particularly with MSH6 and PMS2 gene mutations, the risk of developing certain cancers and the ages of onset may be substantially different than classically reported, both within and among families. In these cases, it may be difficult for at-risk family members to adhere to stringent and invasive surveillance recommendations, especially when family history is not striking for early-onset cancers. The family reported here is a good example of how compliance following current surveillance guidelines may be difficult for at-risk relatives, given the presentation of LS. This has additionally been a challenge in developing consensus management guidelines for LS. LS has been traditionally described in terms of earlyonset colorectal and endometrial cancers. Although this remains a confirmed association, we are learning more about the variability of LS and the prevalence of other cancers associated with this condition. The majority of cases of LS are reported to be caused by MLH1 and MSH2 gene mutations, but as evaluation for this condition becomes more widespread and routine in cases beyond the classically reported presentation, it is likely that we will come to find that the prevalence of other mismatch gene mutations is much higher than previously suspected. In order to further study and define the phenotype of these ''atypical'' LS cases and develop improved screening and management recommendations for these families, it is necessary to further study the efficacy of IHC and MSI on extra-colonic and extra-endometrial tissue, as they are more likely to present with these types of cancers. This case report is an excellent example of how the variable presentation of LS can present challenges for diagnosis, and how MSI/IHC can help clarify the risk for LS in such cases even in non-traditional types of associated cancers.
